The article discusses descriptive statistics of data measured in ordinal and quantitative scales, and criteria for determining the statistical significance of differences between samples when it is impossible to analyze using parametric methods. Special attention is paid to the problem of multiple comparisons of this type of data. For each method, examples of processing data obtained in pharmacological studies are given.

In the article presented the results of research of the influence pharmacokinetics, bioavailability for CNS cyclo-L-prolylglycine to the manifestation of its main pharmacological effects in experimental animals.

Combined oral contraception and treatment of new coronavirus infection (COVID-19): issues of drug interaction This article examines the interaction of combined oral contraceptives with drugs recommended in the treatment of new coronavirus infection (COVID-19) at the pharmacodynamic and pharmacokinetic levels, with an assessment of the effectiveness and safety of therapy for the female body.

A comparative study of the effects of an inorganic lithium salt (lithium carbonate) and an organic lithium salt (lithium ascorbate) on a model of alloxan diabetes mellitus was conducted. The use of lithium ascorbate for a month in experimental alloxan diabetes mellitus facilitates its course – the survival rate of animals increases, the level of glycemia decreases (especially when administered at a dose of 10 mg/kg). Morphometric analysis showed that lithium ascorbate in alloxan diabetes has a neuroprotective effect, which is manifested in a decrease in toxic damage to neurocytes with an increase in the number of cells with reversible changes and intact neurons. Lithium carbonate at doses of 5 and 10 mg / kg was not effective.

The research of immunotoxicity of extended-release form of Afobazol was conducted on male CBA, C57BL/6 and F1 hybrids (CBA×C57BL/6) mice. Afobazol was administered per os for 14 days in doses of 12 mg/kg and 120 mg/kg. Control group received a placebo. Weight of thymus, spleen and popliteal lymph nodes was not affected by the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg in F1 hybrids (CBA×C57BL/6) mice compared to the control group (p> 0.05). Cellularity of thymus was significantly increased by the extended-release form of Afobazol in dose of 12 mg/kg (p< 0.01 vs control group). Administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg decreased spontaneous chemiluminescence activity of peripheral blood lymphocytes in 2.0 and 2.2 times, in dose of 120 mg/kg level integral chemiluminescence response S was decreased in 2.4 times (p< 0.05 vs control group). Phagocytic activity of peritoneal macrophages and antibody production in F1 hybrids (CBA×C57BL/6) mice were not affected by administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg (p > 0.05 vs control group). 14 days of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg did not cause any significant change to intensity of delayed-type hypersensitivity reactions (p> 0.05 vs control group). The results of the study allow us to conclude that administration of the extended-release form Afobazol in the range of studied doses does not induce immunotoxicity.

Presents results of a study of subchronic toxicity of homeopathic drug Dantinorm Baby in finished dosage form. The drug in the form of a ready solution was administered daily orally for one month to outbred rats Infanta and chinchilla rabbits at a dose of 0.3 ml/kg, corresponding to the therapeutic, and 3 ml/kg, exceeding the therapeutic dose 10 times. Clinical, laboratory and histopathological studies performed in accordance with the General Protocol, showed no toxic effects of homeopathic preparation of Dantinorm Baby. The totality of the obtained data of the subchronic experiment indicates that there are no obstacles to the clinical study of the drug Dantinorm Baby in the range of therapeutic dosages.